And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to escort Mrs. Pharmalot to a Rent Party, hang with one of our short people, promenade the official mascot, and catch up on some reading. And what about you? This is a lovely time to enjoy the great outdoors — beaches, lakes, and mountains are beckoning — or think ahead to a summer getaway. Or if you feel like taking a risk, you could place a bet on which countries might offer you-know-who some political dirt. Well, whatever you do, have a grand time. But be safe. And if Dad is around, remember to say hello. Enjoy, and see you soon. …

Bluebird Bio (BLUE) will be selling the world’s second-most expensive drug, now that it has priced its Zynteglo, a gene therapy for a rare blood disorder, at $1.8 million, STAT reports. Only Zolgensma, the Novartis (NVS) gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million. Bluebird is offering to put as much as 80% of Zynteglo revenue at risk — meaning the biotech would not receive payment — if the medicine fails to benefit patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy